3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
18
Observational
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Sexual Dysfunction, Physiological
1
PROMs
1
Neoplasms
1
Locally Advanced Melanoma
1
Eunuchism
1
Erectile Dysfunction
1
Cutaneous Squamous Cell Carcinoma (CSCC)
1
Carcinoma, Basal Cell
1
Advanced Non-small Cell Lung Cancer
1
Interventions
Surveys and Questionnaires
86
Blood Specimen Collection
58
Interviews as Topic
28
Observation
15
Data Collection
15
Radiotherapy
12
Watchful Waiting
11
Magnetic Resonance Spectroscopy
11
Hematologic Tests
11
Exercise
11
Drug Therapy
11
Quality of Life
9
Biopsy
8
Specimen Handling
7
Therapeutics
6
Restraint, Physical
6
Magnetic Resonance Imaging
6
Focus Groups
6
pembrolizumab
5
Standard of Care
5
Rivaroxaban
5
Phlebotomy
5
Nivolumab
5
Lapatinib
5
Immune Checkpoint Inhibitors
5
atezolizumab
4
apixaban
4
Trastuzumab
4
Patient Reported Outcome Measures
4
Palliative Care
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Neoplasms
×
cemiplimab
×
Clear all
NCT05302297
2022-12-13
TOSCA
Sanofi
Completed
305 enrolled